Crispr Therapeutics Ag
(NQ:
CRSP
)
49.87
+2.13 (+4.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
3 Gene-Editing Stocks With the Potential to Mint Millionaires
December 13, 2023
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.
Via
InvestorPlace
Exposures
Product Safety
Cathie Wood's Ark Invest Sells Nearly $11.5M Worth Of Coinbase Shares As Bitcoin, Crypto Rally Loses Steam
December 12, 2023
Via
Benzinga
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
December 12, 2023
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology.
Via
Investor's Business Daily
Exposures
Product Safety
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
December 12, 2023
Intellia is approaching the finish line.
Via
The Motley Fool
Cathie Wood's Ark Dumps $12.8M Worth Of Grayscale Bitcoin Trust Amid Crypto Rally Losing Wind In Sails
December 11, 2023
On Monday, Cathie Wood-led Ark Invest made a significant move by selling over $12.8 million worth of Grayscale Bitcoin Trust (OTC:GBTC) shares, amidst fluctuating cryptocurrency prices.
Via
Benzinga
Is This News a Setback or a Step Forward for CRISPR Therapeutics?
December 06, 2023
It's important to look at the news through a long-term lens.
Via
The Motley Fool
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
December 06, 2023
Via
Benzinga
Why CRISPR Stock Keeps Falling
December 11, 2023
CRISPR just scored its first FDA victory -- but profits remain years away.
Via
The Motley Fool
Exposures
Product Safety
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
December 11, 2023
Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider.
Via
InvestorPlace
HP To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Monday
December 11, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Bull Of The Day: Crispr Therapeutics
December 11, 2023
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old...
Via
Talk Markets
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
December 11, 2023
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.
Via
The Motley Fool
The Latest Analyst Ratings for CRISPR Therapeutics
December 05, 2023
Via
Benzinga
The 3 Best Cathie Wood Stocks to Buy in December
December 10, 2023
Cathie Wood stocks had a great November and are well-positioned to keep performing well, given the favorable macro backdrop.
Via
InvestorPlace
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
December 10, 2023
The big biotech's shares have been on the rise this year.
Via
The Motley Fool
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
December 08, 2023
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y
Via
Benzinga
Exposures
Product Safety
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review
December 08, 2023
Treasury yields and crude oil came off multimonth lows on Friday's jobs report.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Fossil Fuels
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
December 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
December 08, 2023
The timing of the cuts is setting off alarm bells, but the situation is under control.
Via
The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
December 07, 2023
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks.
Via
InvestorPlace
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
December 07, 2023
Shareholders will do well to prepare themselves for how regulators might react.
Via
The Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
December 07, 2023
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.
Via
The Motley Fool
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
December 07, 2023
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.
Via
InvestorPlace
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases
December 05, 2023
Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T
Via
Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
December 05, 2023
One of these stocks may be riskier than the other...
Via
The Motley Fool
The Market's Up This Year. Do You Feel Like You Are Winning?
December 04, 2023
We've also got a look at two stocks worth watching and the popular toys for this holiday season.
Via
The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
December 04, 2023
Vertex shares have soared 400% over the past decade.
Via
The Motley Fool
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today
December 04, 2023
CRISPR Therapeutics' shares advanced in the double-digits this year.
Via
The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
December 03, 2023
The one thing these two stocks have in common is tremendous growth prospects.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.